Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.

Maier FC, Schweifer A, Damaraju VL, Cass CE, Bowden GD, Ehrlichmann W, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G.

Pharmaceuticals (Basel). 2019 Feb 15;12(1). pii: E31. doi: 10.3390/ph12010031.

2.

Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes.

Damaraju VL, Kuzma M, Cass CE, Putman CT, Sawyer MB.

Biochem Pharmacol. 2018 Sep;155:162-171. doi: 10.1016/j.bcp.2018.07.001. Epub 2018 Jul 2.

PMID:
29983397
3.

Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia.

Wanek T, Kreis K, Križková P, Schweifer A, Denk C, Stanek J, Mairinger S, Filip T, Sauberer M, Edelhofer P, Traxl A, Muchitsch VE, Mereiter K, Hammerschmidt F, Cass CE, Damaraju VL, Langer O, Kuntner C.

Bioorg Med Chem. 2016 Nov 1;24(21):5326-5339. doi: 10.1016/j.bmc.2016.08.053. Epub 2016 Aug 29.

PMID:
27614920
4.
5.

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, Kuzma M, Scarfe AG, Clemons M, Tonkin K, Au HJ, Koski S, Joy AA, Smylie M, King K, Carandang D, Damaraju VL, Hanson J, Cass CE, Mackey JR.

Clin Breast Cancer. 2016 Apr;16(2):139-44.e1-3. doi: 10.1016/j.clbc.2015.09.006. Epub 2015 Sep 25.

PMID:
26452313
6.

Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.

Damaraju VL, Kuzma M, Cass CE, Sawyer MB.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1093-8. doi: 10.1007/s00280-015-2859-8. Epub 2015 Sep 2.

PMID:
26330332
7.

Development of a new equation to estimate creatinine clearance in cancer patients.

Chu MP, McCaw L, Stretch C, Butts C, Hanson J, Kuzma M, Damaraju VL, Baracos VE, Sawyer MB.

Cancer Chemother Pharmacol. 2015 Jul;76(1):117-24. doi: 10.1007/s00280-015-2777-9. Epub 2015 May 19.

PMID:
25986679
8.

Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?

Damaraju VL, Kuzma M, Mowles D, Cass CE, Sawyer MB.

Mol Cancer Ther. 2015 Jan;14(1):236-45. doi: 10.1158/1535-7163.MCT-14-0337. Epub 2014 Dec 17.

9.

Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.

Damaraju VL, Mowles D, Wilson M, Kuzma M, Cass CE, Sawyer MB.

Biochem Cell Biol. 2013 Dec;91(6):419-27. doi: 10.1139/bcb-2013-0041. Epub 2013 Jun 17.

PMID:
24219283
10.

Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.

Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan AJ, Cass CE, Sawyer MB.

Clin Cancer Res. 2014 Jan 1;20(1):176-86. doi: 10.1158/1078-0432.CCR-13-2293. Epub 2013 Oct 29.

11.

Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.

Sjuvarsson E, Damaraju VL, Mowles D, Sawyer MB, Tiwari R, Agarwal HK, Khalil A, Hasabelnaby S, Goudah A, Nakkula RJ, Barth RF, Cass CE, Eriksson S, Tjarks W.

J Pharmacol Exp Ther. 2013 Nov;347(2):388-97. doi: 10.1124/jpet.113.207464. Epub 2013 Sep 4.

12.

Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.

Lepist EI, Damaraju VL, Zhang J, Gati WP, Yao SY, Smith KM, Karpinski E, Young JD, Leung KH, Cass CE.

Drug Metab Dispos. 2013 Apr;41(4):916-22. doi: 10.1124/dmd.112.049858. Epub 2013 Feb 6.

PMID:
23388705
13.

Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.

Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z.

Nucleosides Nucleotides Nucleic Acids. 2012;31(3):236-55. doi: 10.1080/15257770.2011.652330.

PMID:
22356238
14.

Influence of sugar ring conformation on the transportability of nucleosides by human nucleoside transporters.

Damaraju VL, Mowles D, Smith KM, Yao SY, Young JD, Marquez VE, Cass CE.

Chembiochem. 2011 Dec 16;12(18):2774-8. doi: 10.1002/cbic.201100567. Epub 2011 Nov 4.

PMID:
22052809
15.

Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

Peng XX, Shi Z, Tiwari AK, Damaraju VL, Fu L, Cass CE, Ashby CR Jr, Kruh GD, Chen ZS.

Oncol Lett. 2011 May;2(3):549-556. Epub 2011 Mar 21.

16.

Molecular biology of nucleoside transporters and their distributions and functions in the brain.

Parkinson FE, Damaraju VL, Graham K, Yao SY, Baldwin SA, Cass CE, Young JD.

Curr Top Med Chem. 2011;11(8):948-72. Review.

PMID:
21401500
17.

Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.

Damaraju VL, Smith KM, Mowles D, Nowak I, Karpinski E, Young JD, Robins MJ, Cass CE.

Biochem Pharmacol. 2011 Jan 1;81(1):82-90. doi: 10.1016/j.bcp.2010.09.009. Epub 2010 Sep 18.

PMID:
20854794
19.

An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.

Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB.

Cancer Chemother Pharmacol. 2011 Jan;67(1):93-101. doi: 10.1007/s00280-010-1288-y. Epub 2010 Mar 5.

PMID:
20204364
20.

Human nucleoside transporters: biomarkers for response to nucleoside drugs.

Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):450-63. doi: 10.1080/15257770903044499. Review.

PMID:
20183595
21.

Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell lines.

Damaraju S, Zhang N, Li N, Tao L, Damaraju VL, Dufour J, Santos C, Sun XJ, Mackey J, Wishart DS, Cass CE, Li L.

Anal Biochem. 2010 Jan 1;396(1):69-75. doi: 10.1016/j.ab.2009.08.019. Epub 2009 Aug 20.

PMID:
19699175
22.

Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2.

Damaraju S, Damaraju VL, Mowles D, Sawyer MB, Damaraju S, Cass CE.

Biochem Pharmacol. 2010 Jan 1;79(1):21-9. doi: 10.1016/j.bcp.2009.07.018. Epub 2009 Aug 4.

PMID:
19660438
23.

Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3.

Elwi AN, Damaraju VL, Kuzma ML, Mowles DA, Baldwin SA, Young JD, Sawyer MB, Cass CE.

Am J Physiol Renal Physiol. 2009 Jun;296(6):F1439-51. doi: 10.1152/ajprenal.90411.2008. Epub 2009 Mar 18.

24.

Renal conservation of folates role of folate transport proteins.

Damaraju VL, Cass CE, Sawyer MB.

Vitam Horm. 2008;79:185-202. doi: 10.1016/S0083-6729(08)00406-8. Review.

PMID:
18804695
25.

Human concentrative nucleoside transporter 3 is a determinant of fludarabine transportability and cytotoxicity in human renal proximal tubule cell cultures.

Elwi AN, Damaraju VL, Kuzma ML, Baldwin SA, Young JD, Sawyer MB, Cass CE.

Cancer Chemother Pharmacol. 2009 Jan;63(2):289-301. doi: 10.1007/s00280-008-0739-1. Epub 2008 May 24.

PMID:
18500522
26.

Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells.

Cai J, Damaraju VL, Groulx N, Mowles D, Peng Y, Robins MJ, Cass CE, Gros P.

Cancer Res. 2008 Apr 1;68(7):2349-57. doi: 10.1158/0008-5472.CAN-07-5528.

27.

Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity.

Damaraju D, Damaraju VL, Brun M, Mowles D, Kuzma M, Berendt RC, Sawyer MB, Cass CE.

Biochem Pharmacol. 2008 May 15;75(10):1901-11. doi: 10.1016/j.bcp.2008.02.006. Epub 2008 Feb 16.

PMID:
18371936
28.

Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine.

Peng XX, Shi Z, Damaraju VL, Huang XC, Kruh GD, Wu HC, Zhou Y, Tiwari A, Fu L, Cass CE, Chen ZS.

Leuk Res. 2008 May;32(5):799-809. Epub 2007 Nov 8.

PMID:
17996297
29.

Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.

Damaraju VL, Bouffard DY, Wong CK, Clarke ML, Mackey JR, Leblond L, Cass CE, Grey M, Gourdeau H.

BMC Cancer. 2007 Jul 3;7:121.

30.

Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney.

Damaraju VL, Elwi AN, Hunter C, Carpenter P, Santos C, Barron GM, Sun X, Baldwin SA, Young JD, Mackey JR, Sawyer MB, Cass CE.

Am J Physiol Renal Physiol. 2007 Jul;293(1):F200-11. Epub 2007 Apr 4.

31.

A study of reproducibility of guanidination-dimethylation labeling and liquid chromatography matrix-assisted laser desorption ionization mass spectrometry for relative proteome quantification.

Ji C, Zhang N, Damaraju S, Damaraju VL, Carpenter P, Cass CE, Li L.

Anal Chim Acta. 2007 Mar 7;585(2):219-26. Epub 2007 Jan 13.

PMID:
17386668
32.

Renal nucleoside transporters: physiological and clinical implications.

Elwi AN, Damaraju VL, Baldwin SA, Young JD, Sawyer MB, Cass CE.

Biochem Cell Biol. 2006 Dec;84(6):844-58. Review.

PMID:
17215872
33.

The role of human nucleoside transporters in cellular uptake of 4'-thio-beta-D-arabinofuranosylcytosine and beta-D-arabinosylcytosine.

Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE.

Mol Pharmacol. 2006 Jul;70(1):303-10. Epub 2006 Apr 14.

PMID:
16617163
34.

A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.

King KM, Damaraju VL, Vickers MF, Yao SY, Lang T, Tackaberry TE, Mowles DA, Ng AM, Young JD, Cass CE.

Mol Pharmacol. 2006 Jan;69(1):346-53. Epub 2005 Oct 18.

PMID:
16234483
35.

Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney.

Damaraju VL, Hamilton KF, Seth-Smith ML, Cass CE, Sawyer MB.

Mol Pharmacol. 2005 Feb;67(2):453-9. Epub 2004 Oct 27.

PMID:
15509714
36.

Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.

Damaraju VL, Visser F, Zhang J, Mowles D, Ng AM, Young JD, Jayaram HN, Cass CE.

Mol Pharmacol. 2005 Jan;67(1):273-9. Epub 2004 Oct 14.

PMID:
15486050
37.

Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy.

Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, Cass CE.

Oncogene. 2003 Oct 20;22(47):7524-36. Review.

PMID:
14576856

Supplemental Content

Loading ...
Support Center